Researchers are looking at a drug once used to improve blood flow in damaged hearts in thousands of patients as a possible treatment option for triple negative breast cancer . Cancer researchers at Houston Methodist Hospital want to know if combining nitric oxide synthase inhibitor Tilarginine Acetate and standard chemotherapy is a safe treatment option for patients with locally advanced or metastatic TNBC.